Downregulation of Low-density lipoprotein receptor-related protein 1B (LRP1B) inhibits the progression of hepatocellular carcinoma cells by activating the endoplasmic reticulum stress signaling pathway

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589–604.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314.
   PubMed Web of Science ®Google Scholar
• Greten TF, Lai CW, Li G, et al. Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterology. 2019;156:510–524.
   PubMed Web of Science ®Google Scholar
• Tang W, Chen Z, Zhang W, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5:87.
   PubMed Web of Science ®Google Scholar
• Strickland DK, Gonias SL, Argraves WS. Diverse roles for the LDL receptor family. Trends Endocrinol Metab. 2002;13:66–74.
   PubMed Web of Science ®Google Scholar
• May P, Woldt E, Matz RL, et al. The LDL receptor-related protein (LRP) family: an old family of proteins with new physiological functions. Ann Med. 2007;39:219–228.
   PubMed Web of Science ®Google Scholar
• Chen H, Chong W, Wu Q, et al. Association of LRP1B mutation with tumor mutation burden and outcomes in melanoma and non-small cell lung cancer patients treated with immune check-point blockades. Front Immunol. 2019;10:1113.
   PubMed Web of Science ®Google Scholar
• Ni S, Hu J, Duan Y, et al. Down expression of LRP1B promotes cell migration via RhoA/Cdc42 pathway and actin cytoskeleton remodeling in renal cell cancer. Cancer Sci. 2013;104:817–825.
   PubMed Web of Science ®Google Scholar
• Elgendy M, Fusco JP, Segura V, et al. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer. Int J Cancer. 2019;145:1991–2001.
   PubMed Web of Science ®Google Scholar
• Principe C, Dionisio de Sousa IJ, Prazeres H, et al. LRP1B: a giant lost in cancer translation. Pharmaceuticals (Basel). 2021;14:836.
   PubMedGoogle Scholar
• Brown LC, Tucker MD, Sedhom R, et al. LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. J Immunother Cancer. 2021;9. DOI:10.1136/jitc-2020-001792.
   Google Scholar
• Liu F, Hou W, Liang J, et al. LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma. J Cancer. 2021;12:4039–4048.
   PubMed Web of Science ®Google Scholar
• Wang L, Yan K, He X, et al. LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma. J Cancer. 2021;12:217–223.
   PubMed Web of Science ®Google Scholar
• Zhen Z, Shen Z, Hu Y, et al. Screening and identification of angiogenesis-related genes as potential novel prognostic biomarkers of hepatocellular carcinoma through bioinformatics analysis. Aging (Albany NY). 2021;13:17707–17733.
   PubMedGoogle Scholar
• Pillai-Kastoori L, Schutz-Geschwender AR, Harford JA. A systematic approach to quantitative Western blot analysis. Anal Biochem. 2020;593:113608.
   PubMed Web of Science ®Google Scholar
• Diermeier-Daucher S, Clarke ST, Hill D, et al. Cell type specific applicability of 5-ethynyl-2’-deoxyuridine (EdU) for dynamic proliferation assessment in flow cytometry. Cytometry A. 2009;75:535–546.
   PubMed Web of Science ®Google Scholar
• Pijuan J, Barcelo C, Moreno DF, et al. In vitro cell migration, invasion, and adhesion assays: from cell imaging to data analysis. Front Cell Dev Biol. 2019;7:107.
   PubMed Web of Science ®Google Scholar
• Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006;1:1458–1461.
   PubMed Web of Science ®Google Scholar
• Cai L, Qin X, Xu Z, et al. Comparison of cytotoxicity evaluation of anticancer drugs between real-time cell analysis and CCK-8 method. ACS Omega. 2019;4:12036–12042.
   PubMed Web of Science ®Google Scholar
• Wei L, Lian B, Zhang Y, et al. Application of microRNA and mRNA expression profiling on prognostic biomarker discovery for hepatocellular carcinoma. BMC Genomics. 2014;15 Suppl 1:S13.
   PubMed Web of Science ®Google Scholar
• Pinyol R, Torrecilla S, Wang H, et al. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. 2021;75:865–878.
   PubMed Web of Science ®Google Scholar
• Powers RK, Goodspeed A, Pielke-Lombardo H, et al. GSEA-InContext: identifying novel and common patterns in expression experiments. Bioinformatics. 2018;34:i555–i564.
   PubMed Web of Science ®Google Scholar
• Liu CX, Musco S, Lisitsina NM, et al. LRP-DIT, a putative endocytic receptor gene, is frequently inactivated in non-small cell lung cancer cell lines. Cancer Res. 2000;60:1961–1967.
   PubMed Web of Science ®Google Scholar
• Tabouret E, Labussiere M, Alentorn A, et al. LRP1B deletion is associated with poor outcome for glioblastoma patients. J Neurol Sci. 2015;358:440–443.
   PubMed Web of Science ®Google Scholar
• Hu S, Zhao X, Qian F, et al. Correlation between LRP1B mutations and tumor mutation burden in gastric cancer. Comput Math Methods Med. 2021;2021:1522250.
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun P, Gao C, et al. Down-regulation of LRP1B in colon cancer promoted the growth and migration of cancer cells. Exp Cell Res. 2017;357:1–8.
   PubMed Web of Science ®Google Scholar
• Bertram JS. The molecular biology of cancer. Mol Aspects Med. 2000;21:167–223.
   PubMedGoogle Scholar
• Lovitt CJ, Hilko DH, Avery VM, et al. Development of ethynyl-2’-deoxyuridine chemical probes for cell proliferation. Bioorg Med Chem. 2016;24:4272–4280.
   PubMed Web of Science ®Google Scholar
• Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol. 2018;13:395–412.
   PubMed Web of Science ®Google Scholar
• Kramer N, Walzl A, Unger C, et al. In vitro cell migration and invasion assays. Mutat Res. 2013;752:10–24.
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–726.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Wei-Qi J, Jin D. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta Rev Cancer. 2020;1874:188382.
   PubMed Web of Science ®Google Scholar
• Pastorelli D, Cartei G, Zustovich F, et al. Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. Ann Oncol. 2006;17(Suppl 5):v153–157.
   PubMedGoogle Scholar
• Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31:3501–3508.
   PubMed Web of Science ®Google Scholar
• Lin RW, Ho CJ, Chen HW, et al. P53 enhances apoptosis induced by doxorubicin only under conditions of severe DNA damage. Cell Cycle. 2018;17:2175–2186.
   PubMed Web of Science ®Google Scholar
• Li X, Wang J, Gong X, et al. Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH. Nucleic Acids Res. 2020;48:8255–8268.
   PubMed Web of Science ®Google Scholar
• Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat Rev Cancer. 2021;21:71–88.
   PubMed Web of Science ®Google Scholar
• Lin Y, Jiang M, Chen W, et al. Cancer and ER stress: Mutual crosstalk between autophagy, oxidative stress and inflammatory response. Biomed Pharmacother. 2019;118:109249.
   PubMed Web of Science ®Google Scholar
• Urra H, Dufey E, Avril T, et al. Endoplasmic reticulum stress and the hallmarks of cancer. Trends Cancer. 2016;2:252–262.
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR, Mohamed E, Rodriguez PC. Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer. J Immunother Cancer. 2017;5:5.
   PubMed Web of Science ®Google Scholar
• Li W, Yang J, Luo L, et al. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. Nat Commun. 2019;10:3349.
   PubMed Web of Science ®Google Scholar
• Riha R, Gupta-Saraf P, Bhanja P, et al. Stressed out - therapeutic implications of ER stress related cancer research. Oncomedicine. 2017;2:156–167.
   PubMedGoogle Scholar
• Boyce M, Yuan J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ. 2006;13:363–373.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500–2501.
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202–206.
   PubMed Web of Science ®Google Scholar
• Rodriguez Benavente MC, Argueso P. Glycosylation pathways at the ocular surface. Biochem Soc Trans. 2018;46:343–350.
   PubMed Web of Science ®Google Scholar
• Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540–555.
   PubMed Web of Science ®Google Scholar
• Hou H, Sun H, Lu P, et al. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma. Mol Cancer Ther. 2013;12:2874–2884.
   PubMed Web of Science ®Google Scholar
• Wu J, Chen S, Liu H, et al. Tunicamycin specifically aggravates ER stress and overcomes chemoresistance in multidrug-resistant gastric cancer cells by inhibiting N-glycosylation. J Exp Clin Cancer Res. 2018;37:272.
   PubMed Web of Science ®Google Scholar
• Shu J, Dang L, Zhang D, et al. Dynamic analysis of proteomic alterations in response to N-linked glycosylation inhibition in a drug-resistant ovarian carcinoma cell line. FEBS J. 2019;286:1594–1605.
   PubMed Web of Science ®Google Scholar